Global herpes zoster burden in adults with asthma: a systematic review and meta-analysis.

Autor:	Mortimer KJ; Cambridge Africa, Department of Pathology, University of Cambridge, Cambridge, UK.; Department of Paediatrics and Child Health, School of Clinical Medicine, College of Health Sciences, University of KwaZulu Natal, Durban, South Africa.; Respiratory Medicine, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK., Cruz AA; ProAR Foundation and Federal University of Bahia, Salvador, Brazil., Sepúlveda-Pachón IT; P95 Epidemiology and Pharmacovigilance, Bogotá, Colombia., Jorga A; GSK, New York, NY, USA., Vroling H; Pallas Health Research and Consultancy, a P95 company, Rotterdam, The Netherlands., Williams C; GSK, Wavre, Belgium charles.t.williams@gsk.com.
Jazyk:	angličtina
Zdroj:	The European respiratory journal [Eur Respir J] 2024 Aug 08; Vol. 64 (2). Date of Electronic Publication: 2024 Aug 08 (Print Publication: 2024).
DOI:	10.1183/13993003.00462-2024
Abstrakt:	Background: Asthma is a common respiratory disease, which may be associated with an increased risk of herpes zoster (HZ), often a debilitating disease associated with severe pain. This is the first systematic review with the objective of summarising evidence on HZ burden in adults with asthma. Methods: A global systematic literature review and meta-analysis was conducted (MEDLINE and Embase, 2003-2024) on HZ burden (incidence, risk and complications) in adults (≥18 years) with asthma. Results: There were 19 studies included on HZ outcomes in adults with asthma. Pooled HZ incidence per 1000 person-years was 5.71 (95% CI 4.68-6.96) in adults aged ≥18 years (4.20 (95% CI 3.09-5.70) in those aged <60 years versus 10.33 (95% CI 9.17-11.64) in those aged ≥60 years). The pooled rate ratio for developing HZ was 1.23 (95% CI 1.11-1.35) in those aged ≥18 years and 1.36 (95% CI 1.15-1.61) in those aged ≥50 years. The risk of HZ was higher in people with asthma using systemic corticosteroids, long-acting β-agonists plus inhaled corticosteroids and "add-on therapy". Asthma was also associated with an increased risk of post-herpetic neuralgia (OR 1.21, 95% CI 1.06-1.37) and HZ ophthalmicus (OR 1.9, 95% CI 1.1-3.2). Differences in study design, setting, case definitions and follow-up durations led to heterogeneity. Conclusions: This systematic literature review and meta-analysis found that adults with asthma have an increased risk of HZ, with higher risks in older age groups and in those on certain treatments, such as oral corticosteroids. HZ vaccines are available for adults, including those with comorbidities such as asthma, and can be considered as part of integrated respiratory care. Competing Interests: Conflict of interest: A. Jorga and C. Williams are employed by GSK. A. Jorga holds shares in Pfizer and GSK. H. Vroling and I.T. Sepúlveda-Pachón are employees of P95/Pallas. P95/Pallas received funding from GSK for the submitted work. P95/Pallas holds/held contracts with AstraZeneca, GSK, Pfizer, Sanofi, Seqirus, Merck, Takeda, Orchard, Biomarin, Daiichi, Bavarian Nordic and Bayer (work for the non-GSK companies was not related to HZ). K.J. Mortimer declares grants and sponsorship from AstraZeneca and GSK to support the Global Asthma Network, consulting fees from AstraZeneca and GSK on asthma and COPD-related advisory boards, and honorarium from GSK for lectures on improving vaccine access for people with asthma, outside the submitted work. A.A. Cruz declares grants and sponsorship from GSK to support the ProAR Foundation, and consulting or lecture fees from Abdi-Ibrahim, AstraZeneca, Boehringer Ingelheim, Chiesi, Crossject, Eurofarma, Farmoquimica, Glennmark, GSK, Mylan, Novartis and Sanofi on asthma-related activities. The authors declare no other financial or non-financial relationships and activities or conflicts of interest. (Copyright ©The authors 2024.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu